Addex Therapeutics Ltd (ADXN)
8.79
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
8.78
-0.01
(-0.11%)
After-Hours: 20:00
Addex Therapeutics Cash from Financing (Quarterly): -0.1643M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.1643M |
| September 30, 2023 | -0.1052M |
| June 30, 2023 | 5.022M |
| March 31, 2023 | 1.110M |
| December 31, 2022 | -0.1342M |
| September 30, 2022 | 4.335M |
| June 30, 2022 | -0.1419M |
| March 31, 2022 | -0.8059M |
| December 31, 2021 | 8.965M |
| September 30, 2021 | -0.1708M |
| Date | Value |
|---|---|
| June 30, 2021 | -0.5673M |
| March 31, 2021 | 9.720M |
| December 31, 2020 | 0.5315M |
| September 30, 2020 | -0.1203M |
| June 30, 2020 | -0.1447M |
| March 31, 2020 | -0.217M |
| December 31, 2019 | -0.089M |
| September 30, 2019 | -0.0927M |
| June 30, 2019 | -0.1717M |
| March 31, 2019 | -0.1133M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.8059M
Minimum
Mar 2022
9.720M
Maximum
Mar 2021
1.408M
Average
-0.1203M
Median
Sep 2020
Cash from Financing (Quarterly) Benchmarks
| AC Immune SA | -0.7872M |
| CRISPR Therapeutics AG | 305.93M |
| NLS Pharmaceutics Ltd | -- |
| Molecular Partners AG | -0.3157M |
| MoonLake Immunotherapeutics | 50.98M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -0.5563M |
| Cash from Investing (Quarterly) | -0.0012M |
| Free Cash Flow | -8.908M |
| Free Cash Flow Per Share (Quarterly) | -0.775 |
| Free Cash Flow to Equity (Quarterly) | -0.5575M |
| Free Cash Flow to Firm (Quarterly) | -0.5575M |
| Free Cash Flow Yield | -163.8% |